ArticleClinical and experimental nephrology2026
Epidemiological analysis of kidney involvement in systemic lupus erythematosus using the national database of designated intractable diseases of Japan: a cross-sectional study of renewal applicants.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the prevalence of active kidney involvement and its associations with comorbidities and treatment patterns among patients with systemic lupus erythematosus (SLE) at renewal application for the Designated Intractable Diseases of Japan.
methodsWe analyzed Medical Certificates of Designated Intractable Diseases that were submitted in 2016 for the renewal of SLE designation. Among 35,207 digitized patients (mean age, 51.1 ± 15.7 years), active kidney involvement was defined as proteinuria (≥ 0.5 g/day) and/or urinary casts (granular casts or red blood cell casts) recorded as Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) items during the 6 months preceding the renewal application.
resultsActive kidney involvement was identified in 8273 patients (23.5%). Compared with those without active kidney involvement, patients with active kidney involvement had a younger mean age at disease onset (32.6 ± 15.3 vs. 34.1 ± 15.2 years) and a lower proportion of females (84.3% vs. 90.5%). They more frequently had comorbid infection (14.6% vs. 10.6%), diabetes mellitus (16.2% vs. 11.2%), and hypertension (43.6% vs. 25.6%), and had higher disease activity (mean SLEDAI, 14.8 ± 9.4 vs. 7.0 ± 6.4). Glucocorticoid use was more common (94.9% vs. 91.8%), fewer patients received ≤ 7.5 mg/day (45.9% vs. 59.2%), and concomitant immunosuppressant use was higher (60.8% vs. 44.1%).
conclusionApproximately one-quarter of Japanese patients with SLE undergoing renewal had active kidney involvement, which was associated with higher disease activity, more comorbidities (notably hypertension), and greater use of glucocorticoid and immunosuppressants.
Indexed as
Identifiers
41945004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.